SEC Filings TLDR

Isaac Manke, a director at Q32 Bio Inc., was granted 53,521 stock options on October 23, 2025. The options, which are for the purchase of common stock, have an exercise price of $2.80 per share and expire on October 22, 2035. The options will vest and become exercisable in full on the earlier of October 23, 2026, or th...

On October 23, 2025, Xu Diyong, a director of Q32 Bio Inc., was granted 53,521 stock options with the right to buy common stock at an exercise price of $2.80 per share. The options are set to vest and become exercisable in full by October 23, 2026, or at the date of the issuer's next annual meeting of stockholders, whi...

Thistle Mary, a director of Q32 Bio Inc., acquired 53,521 stock options on October 23, 2025. The options, which grant the right to buy common stock at $2.80 per share, will vest and become exercisable in full by October 23, 2026, or at the date of the issuer's next annual meeting of stockholders, whichever is earlier, ...

On October 23, 2025, Q32 Bio Inc. granted 53,521 stock options to David S. Grayzel, a director of the company. The options, which are exercisable at $2.80 per share, will vest and become exercisable in full upon the earlier of October 23, 2026, or the date of the company's next annual meeting of stockholders, subject t...

Arthur Tzianabos, a director of Q32 Bio Inc., was granted 53,521 stock options on October 23, 2025. The options, which are for the purchase of common stock at an exercise price of $2.80 per share, will vest and become exercisable in full on the earlier of October 23, 2026, or the date of the company's next annual meeti...

Kathleen LaPorte, a director of Q32 Bio Inc., was granted 53,521 stock options on October 23, 2025. The options, which are exercisable at $2.80 per share, will vest and become exercisable in full upon the earlier of October 23, 2026, or the date of the issuer's next annual meeting of stockholders, subject to LaPorte's ...

On October 23, 2025, Farhad Nanji, a director of PennyMac Financial Services, Inc., received 253 shares of common stock in lieu of cash compensation for services rendered as a non-management director during the previous quarter. This transaction is exempt under Rule 16b-3 of the Securities Exchange Act of 1934. Followi...

On October 23, 2025, Joseph F. Mazzella, a director of PennyMac Financial Services, Inc. (PFSI), acquired 270 shares of common stock at a price of $116.57 per share. This transaction was exempt under Rule 16b-3 of the Securities Exchange Act of 1934, as the shares were received in lieu of cash compensation for services...

David Spector, Chairman & CEO of PennyMac Financial Services, Inc., engaged in multiple stock transactions on October 23, 2025. He acquired 71,161 shares of Common Stock at a weighted average price of $128.0476 and disposed of a total of 71,161 shares in three separate transactions at weighted average prices ranging fr...

Lawrence Steinman, a director of Pasithea Therapeutics Corp., was awarded 242,913 stock options on October 24, 2025, with an exercise price of $0.715 per share. The options, which are set to expire on October 23, 2035, will fully vest on the one-year anniversary of the grant date, provided Steinman remains a director t...

On October 24, 2025, Daniel H. Schneiderman, the Chief Financial Officer of Pasithea Therapeutics Corp., was awarded 317,266 stock options under the company's 2023 Stock Incentive Plan. The options, which grant the right to buy common stock at $0.715 per share, will vest over three years, with 33% vesting after one yea...

Alfred J. Novak, a director of Pasithea Therapeutics Corp., was granted 42,913 stock options on October 24, 2025, with an exercise price of $0.715 per share. The options are set to vest fully on the one-year anniversary of the grant date, provided Novak remains a director through that date. Additionally, the options wi...

Tiago Marques, the Chief Executive Officer of Pasithea Therapeutics Corp., was granted 493,341 stock options on October 24, 2025. The options, which are exercisable at $0.715 per share, vest over three years, with 33% vesting after one year and the remainder in equal quarterly installments over the next two years. The ...

On October 24, 2025, Pasithea Therapeutics Corp. granted 42,913 stock options to its director, Emer Leahy, under the company's 2023 Stock Incentive Plan. The options, which are exercisable at $0.715 per share, vest fully on the one-year anniversary of the grant date, provided that Dr. Leahy remains a director through t...

Simon Dumesnil, a director of Pasithea Therapeutics Corp., was awarded 42,913 stock options on October 24, 2025, under the company's 2023 Stock Incentive Plan. The options, which grant the right to buy common stock at $0.715 per share, will fully vest on the one-year anniversary of the grant date, provided Dumesnil rem...

On October 23, 2025, Karen Lynette McKee, Senior Vice President of Franchising at Potbelly Corp, disposed of 15,855 shares of common stock at $17.12 per share, resulting in zero shares remaining. Additionally, McKee disposed of 16,347 Performance Stock Units (PSUs) at the same price per share, also resulting in zero sh...

Patrick James Walsh, Chief People Officer of Potbelly Corp, disposed of 36,148 shares of common stock and 40,130 performance stock units on October 23, 2025, following the merger of Potbelly Corp with RaceTrac, Inc. The merger resulted in the conversion of each share of common stock into $17.12 in cash. The performance...

David Scott Daniels, SVP and Chief Marketing Officer of Potbelly Corp, disposed of all his holdings in the company following its merger with RaceTrac, Inc. On October 23, 2025, Daniels sold 134,179 shares of common stock at $17.12 per share, resulting in zero post-transaction shares. Additionally, he disposed of 56,998...

On October 23, 2025, Dixon Adiya, SVP, CLO and Secretary of Potbelly Corp, disposed of 155,912 shares of common stock at $17.12 per share, resulting in zero shares remaining. This transaction occurred following the merger of Potbelly Corp with RaceTrac, Inc., where each share of common stock was converted into the righ...

Steven Cirulis, SVP, CFO, and Chief Strategy Officer of Potbelly Corp, disposed of all his holdings in the company following its merger with RaceTrac, Inc. The merger, effective October 23, 2025, converted each share of Potbelly Corp common stock into $17.12 in cash. Cirulis disposed of 417,470 shares of common stock a...

Douglas Jeffrey, the SVP and Chief Information Officer of Potbelly Corp, disposed of a significant number of shares following the merger of Potbelly Corp with RaceTrac, Inc. The merger, effective on October 23, 2025, resulted in the conversion of each share of Potbelly Corp's common stock into $17.12 in cash. Jeffrey d...

On October 23, 2025, Adrian M. Butler, a director of Potbelly Corp, disposed of 89,529 shares of common stock at a price of $17.12 per share. This transaction was part of the merger agreement between Potbelly Corp, RaceTrac, Inc., and Hero Sub Inc., where each share of common stock was converted into the right to recei...

On October 23, 2025, Sutton Jill, a director of Potbelly Corp, disposed of 77,304 shares of common stock at a price of $17.12 per share. This transaction was part of the merger agreement between Potbelly Corp, RaceTrac, Inc., and Hero Sub Inc., which resulted in the cancellation and conversion of each share of common s...

Joseph Boehm, a director of Potbelly Corp, disposed of 248,826 shares of common stock on October 23, 2025, following the merger of Potbelly Corp with RaceTrac, Inc. The shares were converted into cash at a rate of $17.12 per share, as per the merger agreement. This transaction resulted in Boehm holding no shares of Pot...

On October 23, 2025, POTBELLY CORP (PBPB) completed a merger with RaceTrac, Inc. and Hero Sub Inc., resulting in the cancellation of all outstanding shares of Common Stock. Each share was converted into the right to receive $17.12 in cash. Will Atkins, VP and Controller of POTBELLY CORP, disposed of 48,203 shares of Co...